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A monoclonal ntibody (SB-4) to human Clq was prepared. The equilibrium constant of the antibody for CI q was found 
to be greater than 10 ~° M -1. It has been shown that the antibody binds to the A-B chain dimer, probably via the B 
chain of Clq. Pepsin digestion of Clq at pH 4.5, which fragments the globular regions but leaves the collagenous region 
intact, allowed the demonstration that the antigenic site is located in the collagenous region of the molecule. The effect 
of the antibody on haemolytic a tivity has shown that it is capable of inhibiting the formation of EAC1 cells from EAClq 
cells plus Clr and Cls but is incapable of inhibiting the CI activity of preformed EAC1 cells. This indicates that the 
binding of the antibody to the collagenous portion of the B chain of Clq probably prevents interaction between Clq 
and the Clr2-Cls z complex. 
Clq; Monoclonal ntibody; C]rz-Cls 2 complex; Antigenic site; Binding site; Complement 
1. INTRODUCTION 
The classical pathway of complement activation 
is initiated by the activation of C1. C1 is composed 
of  one molecule of C lq  and two molecules each of 
C l r  and Cls. Activation of C1 proceeds by three 
distinct steps: (i) binding of C lq  to the Fc region 
of antibody in immune complexes, which may lead 
to a conformationai change in Clq;  (ii) 
autocatalytic activation of C l r  to Cir;  (iii) activa- 
tion of Cls  to Cis  by Cir ,  resulting in the activated 
form of  C1, Ci .  A number of  models for the mode 
of  activation have recently been proposed [1-3]. 
C lq  consists of 18 polypeptide chains (6A, 6B, 
6C) which form nine disulphide-linked dimers (6A- 
B, 3C-C). Amino acid sequence data have revealed 
that each chain consists of an N-terminal col- 
lagenous region approx. 80 residues in length, the 
remainder being globular in structure [4]. The 
collagen-like regions of one A, one B and one C 
chain are considered to form a triple helix. 
The relationship between the structure and func- 
tion of  C lq  has been studied by monoclonal anti- 
C lq  antibodies in several aboratories. Since the 
epitopes in C lq  against which the monoclonal an- 
tibodies" are directed are different, the effect 
mediated by these monoclonals varies [5-8]. Here 
we report a monoclonal antibody which recognises 
the collagenous region of C lq,  it reacts with the A- 
B chain dimer and inhibits the haemolytic activity 
of  C lq  if added before the C1 complex is formed. 
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2. MATERIALS AND METHODS 
Human citrated plasma was obtained from Oxford Regional 
Blood Transfusion Service and dotted by addition of CaCI2. 
DEAE Sephacel and CNBr-activated Sepharose 413 were from 
Pharmacia. 1251 carrier-free and nitrocellulose paper were from 
Amersham, England. Pepsin was from Sigma nd perioxidase 
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conjugated rabbit anti-mouse IgG was from Miles, England. 
Balb/c mice were from the Shanghai Institute of Cell Biology, 
Chinese Academy of Science. The Sp2/o cell line was kindly 
provided by Professor R.X. Liu (Chinese Academy of Medical 
Science, Beijing, China). 
2.1. Preparation of complement components 
Clq was prepared as described by Reid [9]. The collagenous 
fragment of C lq was prepared by pepsin digestion [10,11]. The 
concentrations of Clq and of the collagenous fragment were 
determined by amino acid analysis. Other complement com- 
ponents were prepared by published methods: C2 [12], C4 [13], 
c1 [14]. 
2.2. Monoclonal ntibody SB-4 
Balb/c mice were immunised subcutaneously with 40/Ag Clq 
per mouse emulsified in complete Freunds adjuvant wice at 
2-week intervals. 10 days after the second immunisation the 
mice were bled and the sera were tested by enzyme-linked im- 
munosorbent assay (ELISA) [15] for antibodies to Clq. The 
mouse with the highest serum anti-Clq titre was intravenously 
injected with 10/~g Clq on 3 consecutive days [16]. On the 
following day spleen cells were fused with Sp2/o cells [17]. 
Culture supernatants were screened for antibodies to Clq by 
ELISA. One hybrid-producing antibody to Clq was cloned by 
limiting dilution and called Shanghai B-4 (SB-4). Relatively 
large amounts of antibody were produced by transfer of the 
hybrid cells into the peritoneal cavities of fresh mice and 
harvesting the ascites fluid. 
2.3. Purification of antibody and preparation of affinity 
column 
The monoclonal anti-Clq was precipitated from ascites fluid 
by addition of Na2SO+ to 20% (w/v). After centrifugation the 
precipitate was dissolved in 25 mM Tris-HCl, pH 7.4, and 
dialysed extensively against the same buffer. The antibody solu- 
tion was applied to a column of DEAE-SCphacel (Pharmacia) 
1.8 x 12 cm equilibrated with 25 mM Tris-HC1, pH 7.4. Under 
these conditions the antibody was bound to the column and was 
eluted by a linear gradient from starting buffer to the same buf- 
fer containing 200 mM NaCI. Specific antibody was detected by 
a binding assay and was found to be pure as judged by 
SDS-PAGE. 
An affinity column was prepared by binding approx. 7.5 mg 
antibody to 1 g CNBr-activated Sepharose 413 (Pharmacia) 
following the manufacturer's instructions. 10 ml human serum 
made 2.5 mM with DFP was applied to the anti-Clq 
monoclonal antibody Sepharose column, at a flow rate of 
10 ml/h. The column was washed with 140 mM NaC1, 20 mM 
EDTA, 25 mM Tris-HCl, pH 7.4, followed by the same buffer 
with 500 mM NaCI until the A2s0 approached zero. The bound 
Clq was eluted with 140 mM NaCI, 50 mM diethanolamine, 
pH 11.5, and fractions were immediately neutraiised with solid 
giycine. 
2.4. Immunoblotting 
12% SDS polyacrylamide gels [18] were run and proteins 
were blotted onto nitrocellulose asin [19]. After treatment with 
antibody, specific binding was detected using peroxidase- 
conjugated rabbit anti-mouse IgG followed by development 
with 4-chloro-l-naphthol and H202 [19]. 
2.5. Serology 
To measure the affinity of binding of SB-4 to Clq, fixed 
amounts of antibody were mixed with varying amounts of an- 
tigen until the antigen-antibody interaction had come to 
equilibrium (24 h). The amount of free antibody present at 
equilibrium in each mixture was then determined using a solid- 
phase radioimmunoassay [19]. The affinity was calculated from 
a plot of free antibody concentration vs total antigen added 
[19]. 
2.6. Clq haemolytic assay 
Sheep erythrocytes coated with rabbit antibody (EA) were 
prepared as described by Mayer [20]. Clq-depleted serum 
(ClqD) was prepared by passing human serum through an SB-4 
monoclonal anti-Clq column. Haemolytic assays were per- 
formed as follows. 
EA cells (1 x l0 T) with different amounts of purified Clq in 
150/zl DGVB 2+ were incubated at 0°C for 30 min followed by 
2 rain at 37°C. 100/A ClqD 1/500 iii I~VB 2+ was added and 
incubated for 30 rain at 4°C followed~by 2 rain at 37°C. The 
mixture was centrifuged at 1000 x g for 10 rain. The superna- 
tant was removed and the cells resuspended in 100/zl DGVB 2+. 
100/~1 DGVB 2+ containing excess human C4 and C2 was added 
and incubated at 37 °C for 15 rain. Finally 200/~1 of 1/40 guinea 
pig serum in GVB-EDTA was added and incubated at 37°C for 
30 min. 1 ml cold saline was added to stop the reaction and the 
A412 of the supernatant determined after centrifugation at 
1000 x g for 10 rain to remove uulysed cells. 
Z values were determined [20] and the amount of Clq giving 
approx. 75% lysis (i.e. Z = 1.31) was chosen for subsequent ex- 
periments. This was found to be 2.6 ng per tube for inhibition 
assays. Various concentrations of SB-4 monoclonal nti-C lq or 
MRC OX7 monoclonal anti-Tbyl [21] were added at various 
stages during the assay and in all cases Clq at 2.6 rig/tube was 
used. Antibody was incubated: (i) with Clq prior to addition to 
EA cells; (ii) with EACIq cells prior to addition of CIqD; (iii) 
with EACI cells prior to addition of C4 and C2; for 15 rain at 
37°C and the assay continued as described above. Percentage 
inhibition of baemolysis was calculated and plotted vs antibody 
added. 
3. RESULTS AND DISCUSSION 
The  SB-4 ant ibody  a f f in i ty  co lumn gave a good  
yield o f  C lq  (0.6 mg f rom 10 ml  outdated  plasma) 
and the  breakthrough peak f rom the a f f in i ty  col-  
umn was useful  as a reagent  in the haemoly t i c  
assay o f  C lq .  
Western  b lot  analysis o f  the ant ibody  is shown 
in f ig.1. Lanes 3,4 show a b lot  sta ined with amido  
b lack  and lanes 1,2 the same samples incubated 
wi th  SB-4, fo l lowed by per iox idate -con jugated  
rabbi t  ant i -mouse  IgG.  Bound ant ibody  has been 
v isual ised by deve lopment  with ch lo ronaphtho l .  
T racks  1,3 conta in  reduced C lq  and t racks 2,4 
conta in  unreduced  C lq .  It  can  be seen that  the an- 
t ibody  b inds to the A -B  cha in  d imer  o f  C lq  under  
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Fig.l. Western blots of Clq with SB-4. Tracks: 1, reduced Clq 
detected using SB-4; 2, unreduced Clq detected using SB-4; 3, 
reduced Clq stained with amido black; 4, unreduced Clq stain- 
ed with amido black. 
non-reducing conditions. After reduction C lq A 
and B chains are not well separated, but close in- 
spection indicates that SB-4 is probably binding to 
the B chain. 
Fig.2 shows the result of  adding varying quan- 
tities of pure C lq  to a fixed amount of ~zSI-labelled 
antibody and determining the fraction of antibody 
that remains uncomplexed with antigen at 
equilibrium. Preliminary experiments showed that 
equilibrium was fully established within 24 h. Also 
plotted is the theoretical relationship between o70 
binding and the concentration [Ao] of C lq  on the 
assumption that the antibody binds irreversibly to 
the antigen. C lq  has up to six antigen sites per 
molecule but it is probable that steric hindrance 
prevents all of  these binding antibody 
simultaneously. The data in fig.2 were obtained us- 
ing a nominal antibody concentration of 4.75 nM. 
Given that 60-70O7o of this is active antibody [21] 
and that, as fig.2 shows, 50°7o neutralization of  the 
antibody occurred at a C lq  concentration of 
0.7-0.8 nM, it appears that 3 -4  of the C lq  an- 
tigenic sites are simultaneously accessible to an- 
tibody. The departure of the experimental data 
from the theoretical curve obtained assuming ir- 
reversible binding is too small to allow a precise 
evaluation of the antibody affinity but it is 
estimated to be in excess of 10 ]° M -1 [19]. 
C lq  was digested with pepsin to yield a fragment 
which was shown by SDS-PAGE and amino acid 
; analysis to be the collagenous region of C lq  [10]. 
When binding assays were performed using this 
Fig.2. Inhibition of binding of SB-4 to Clq-coated microtitre 
plates by Clq (o) and the collagenous region of Clq (i). A 
theoretical curve based on the assumption that the equilibrium 
constant of the antibody is o= is also shown (o). To calculate 
this curve the antibody concentration has been taken to be 
3.0 nM and the number of accessible antigenic sites, per Clq 
molecule, qual to 3. 
material it was found to be almost as effective as 
C lq  in inhibiting the binding of SB-4 to Clq-  
coated plates (fig.2). This indicates that the epitope 
recognised by SB-4 resides within the collagenous 
region of C lq.  
A C 1 q haemolytic assay was developed in which 
monoclonal antibody could be added to various 
stages in the reaction to test whether inhibition of 
activity occurred. Addition of either no antibody 
or anti-Thyl monoclonal antibody (MRC OX-7) at 
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i~]g.3. Inhibition of CI haemolytic activity by SB-4 anti-Clq 
monoclonal ntibody. The inhibition of haemolysis is shown 
when SB-4 was added at various tages during the assay; (a) an- 
tibody added to Clq before addition of EA cells; (u) antibody 
added after formation of EAClq cells; (o) added after forma- 
tion of EAClqrs but before addition of C4 and C2. 
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any stage in the haemolytic assay did not inhibit 
lysis of the target erythrocytes. When various 
amounts of SB-4 were mixed with Clq before addi- 
tion of EA cells 50~/0 inhibition of activity was 
observed with an antibody concentration of 
around 0.1/zg/ml. A similar result was obtained 
when antibody was added after the formation of 
EAClq cells. However, when antibody was added 
to EAClqrs cells prior to addition of C4 and C2, 
no inhibition of lysis occurred, even at levels 
100-fold higher than that which caused 50% in- 
hibition when the antibody was added before Clr 
and Cls. 
The SB-4 monoclonal antibody thus appears to 
bind to, or mask, the site(s) in the Clq molecule 
which are important for binding the Clr2-Cls2 
complex. As judged by the Western blotting data 
this site appears to involve the collagen-like por- 
tion of the B chain. 
These results support models of C1 in which it is 
proposed that Clr2-Cls2 is closely associated with 
collagen-like regions of Clq in the C1 complex [1]. 
Activation of C1 by immune aggregates in plasma 
results in the rapid removal of C|r and C|s by the 
C1 inhibitor which thus leaves the collagen-like 
regions of Clq free to interact with the widespread 
Clq receptor which has the potential to fulfil a 
number of effector functions [22] such as cell- 
mediated cytotoxicity, inhibition of II-1 produc- 
tion and stimulation of oxidative metabolism. The 
SB-4 monoclonai antibody may be a useful tool in 
the study of the interaction between Clq and its 
receptors. 
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